eligibility_summary
Eligibility: Treatment‑naive Stage I (T<4 cm) adenocarcinoma NSCLC, R0 resection, no evidence of disease, pre‑surgical ctDNA+ (IA/IB) or Stage IB with high‑risk features (VPI, LVI, high‑grade), ECOG 0–1, >6‑mo life expectancy, recovered from surgery, adequate marrow/organ function. Exclude: EGFR/ALK alterations, ILD/pneumonitis, poor lung function, recent other cancer, severe systemic disease, autoimmune (exceptions), active TB/HBV/HCV/HA/uncontrolled HIV, immunodeficiency, corneal disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase III adjuvant NSCLC trial testing: 1) Datopotamab deruxtecan (Dato‑DXd), an antibody–drug conjugate targeting TROP2, the anti‑TROP2 IgG delivers a topoisomerase‑I inhibitor (DXd) into TROP2+ tumor cells, causing DNA damage and bystander killing. 2) Rilvegostomig (AZD2936), a bispecific monoclonal antibody that blocks PD‑1 and TIGIT checkpoints to restore T‑cell/NK‑cell activity via PD‑1/PD‑L1 and TIGIT/CD155 pathways. Arms: Dato‑DXd + rilvegostomig, rilvegostomig alone, versus standard of care (observation or chemotherapy: cisplatin/carboplatin—DNA crosslinkers, etoposide—topoisomerase II inhibitor, pemetrexed—antifolate inhibiting TS/DHFR, vinorelbine—microtubule inhibitor, UFT—oral 5‑FU prodrug inhibiting TS). Targets: TROP2 on tumor cells, PD‑1/TIGIT on lymphocytes, DNA replication/repair and microtubules with chemo.